← Back to Search

GnRH Antagonist

PPOS group for Progestin-Ovarian Stimulation

Phase 3
Recruiting
Research Sponsored by ShangHai Ji Ai Genetics & IVF Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 month after oocyte retrieval
Awards & highlights

Study Summary

This randomized trial aims to compare the euploid rate of blastocysts between PPOS and GnRH antagonist protocols in patients undergoing PGT-A. Infertile women who have medical indication for PGT-A will be recruited for study after explanation and counseling if they fulfill the inclusion criteria and do not have the exclusion criteria. Eligible women will be randomised into one of the two groups: Antagonist group: Women will receive antagonist once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger. PPOS group: Women will receive oral Duphaston 10mg bd from Day 3 till the day of ovulation trigger. The primary outcome is the euploidy rate of blastocysts.

Eligible Conditions
  • Euploidy
  • Progestin-Ovarian Stimulation
  • Preimplantation Genetic Testing
  • Gonadotropin-Releasing Hormone Antagonist

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 month after oocyte retrieval
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 month after oocyte retrieval for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
euploidy rate
Secondary outcome measures
biochemical pregnancy
birthweight of newborns
clinical pregnancy
+12 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: PPOS groupExperimental Treatment1 Intervention
Women will receive oral Duphaston 10mg bd from Day 3 till the day of ovulation trigger.
Group II: Antagonist groupActive Control1 Intervention
Women will receive antagonist (Cetrotide 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger.

Find a Location

Who is running the clinical trial?

ShangHai Ji Ai Genetics & IVF InstituteLead Sponsor
24 Previous Clinical Trials
10,883 Total Patients Enrolled
XIAOXI SUN, PHDStudy DirectorShanghai JiAi Genetics & IVF Institute
6 Previous Clinical Trials
3,388 Total Patients Enrolled
~30 spots leftby Dec 2024